Occam Places Adrian Schreyer as CTO of Anagenex
In March of 2024, Occam placed Adrian Schreyer as CTO at Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines.
Prior to joining Anagenex, he spent over a decade at Exscientia where he was a founding member of the team and went on to support the company through a successful IPO while building its AI team from scratch and eventually serving as the company’s Chief Technology Officer. The AI-enabled drug discovery engine he designed at Exscientia is one of the only AI platforms to drive compounds from discovery into the clinic. Adrian holds a B.Sc. in Applied Biology from the Bonn-Rhein-Sieg University of Applied Sciences and a Ph.D. in Structural Bioinformatics and Drug Discovery from the University of Cambridge.
Schreyer is the latest in a series of Occam placements at Anagenex including Ryan Kruger, CSO, Joe Franklin,SVP Early Discovery and Tito Serafini, Board Member.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.